In a recent advanced-stage study, an investigational drug, Dato-DXd, developed collaboratively by AstraZeneca Plc and Daiichi Sankyo Co., demonstrated its potential in extending the lifespans of certain lung cancer patients.
In earlier studies, the drug had already proved its ability to pause the progression of cancer. In the current study, researchers evaluated the data to determine if the drug could help extend the overall survival rate of patients, a critical benchmark in cancer treatment.
Dato-DXd, also known as datopotamab deruxtecan, is a form of antibody drug-conjugate. Its primary function is to carry a potent chemotherapy directly to the cancer cells, eliminating them while preserving the healthy cells.
AstraZeneca released a statement on Monday stating that the study did not find a statistically significant survival benefit across all test participants. However, a positive outcome was observed for patients diagnosed with non-squamous non-small cell lung cancer, a group that included approximately 75% of the patients involved in the trial. All patients in this group had previously undergone at least one different treatment regimen for the disease.
The promising data collected from this study will aid in continuous dialogue with regulatory authorities across the world to potentially expedite the availability of datopotamab deruxtecan to patients, stated Ken Takeshita, the Head of Research and Development at Daiichi, in a recent press statement.